European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-05-27

Transglutaminase in disease: a novel therapeutic target?

Cel

TRANSPATH is a multisectorial Network designed to facilitate the exchange of knowledge and technology between 7 leading European research teams and 3 SME partners and 2 associate SME Partners involved in basic and applied research into transglutaminase (TG) related human diseases. Its ambitions are to accelerate the development of new strategies for the treatment and diagnosis of human diseases related to transglutaminases, including metastatic cancer, neurodegeneration and celiac disease. The subject is highly relevant as deregulation of tissue transglutaminase activity is observed in a number of human diseases while the exact mechanisms are still largely unknown. The project targets this unmet clinical need. The main objectives are :1) to establish the molecular nature of the role of transglutaminases in the pathogenesis of diseases which are known to involve these multifunctional enzymes with a view to developing novel specific inhibitors and new therapeutic approaches which will have a major impact on their treatment ;2) provide an extensive cross sectorial scientific and supporting training network that will increase the capabilities of highly skilled researchers for the European biotechnology industry and academia.

Zaproszenie do składania wniosków

FP7-PEOPLE-2011-ITN
Zobacz inne projekty w ramach tego zaproszenia

Koordynator

ASTON UNIVERSITY
Wkład UE
€ 795 367,01
Adres
ASTON TRIANGLE
B4 7ET Birmingham
Zjednoczone Królestwo

Zobacz na mapie

Region
West Midlands (England) West Midlands Birmingham
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Martin Griffin (Prof.)
Linki
Koszt całkowity
Brak danych

Uczestnicy (10)